TrialThe Journal of dermatology2025

Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials.

Akimichi Morita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.